Impact of endoscopic ultrasound-guided tissue acquisition on prognosis and peritoneal lavage cytology in resectable or borderline resectable pancreatic ductal adenocarcinoma
-
Published:2024-08
Issue:5
Volume:24
Page:787-795
-
ISSN:1424-3903
-
Container-title:Pancreatology
-
language:en
-
Short-container-title:Pancreatology
Author:
Maruo Motonobu, Ikeura TsukasaORCID, Takaori AyakaORCID, Ikeda Masatoshi, Nakamaru KohORCID, Ito Takashi, Masuda Masataka, Mitsuyama Toshiyuki, Nakayama Shinji, Shimatani Masaaki, Takaoka MakotoORCID, Shibata NobuhiroORCID, Boku Shogen, Yasuda Tomoyo, Miyazaki HidetakaORCID, Matsumura Kazuki, Yamaki So, Hashimoto DaisukeORCID, Satoi Sohei, Naganuma Makoto
Reference37 articles.
1. Cancer statistics, 2023;Siegel;CA A Cancer J Clin,2023 2. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study;Motoi;J Gastroenterol,2019 3. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial;Jang;Ann Surg,2018 4. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized Phase III PREOPANC trial;Versteijne;J Clin Oncol,2020 5. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05);Satoi;J Clin Oncol,2019
|
|